LOUISVILLE, Ky. — IN8bio Inc., a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies that utilize its DeltEx platform, today announced it has selected the UofL Health – Brown Cancer Center GMP Manufacturing Facility at the University of Louisville, home of the Dunbar CAR T-Cell Program, as its manufacturing partner for INB-400. The collaboration provides IN8bio exclusive access to a state-of-the-art GMP manufacturing facility and is structured to support the Company’s anticipated INB-400 Phase 2 clinical program in glioblastoma.
“Since their inception, the UofL Health – Brown Cancer Center GMP Manufacturing Facility and these lifesaving immunotherapies to adult and pediatric cancer patients throughout Kentucky and the region. This manufacturing agreement with IN8bio will allow our facility to provide these groundbreaking immunotherapies for patients throughout the United States,” said James Cripps, Ph.D., manager of the Brown Cancer Center GMP Manufacturing Facility.
“It is with the greatest excitement for the Evan Dunbar Foundation CAR T-cell program that we announce that IN8bio has joined us in this world-changing research,” said Thomas E. Dunbar. “Along with the amazing work at the University of Louisville, I believe that IN8bio can join with us in achieving the goals of the Evan Dunbar Foundation CAR T-cell program. These three organizations working together will create trials that will impact hundreds, if not thousands of patients.
“I am so honored and pleased to see our vision of cancer research come closer to trial and real-time treatment of patients. This has been my lifelong dream and is the most fulfilling way to honor my son, Evan Dunbar, my wife, Dr. Stephanie Altobellis, my father, Wallace and the rest of my family.”
The Dunbar CAR T-Cell Program was created in 2019 thanks to a $1-million pledge from Dunbar, a Louisville resident. It is a state-of-the-art manufacturing facility custom-built to collaborate with the biotech industry to advance cutting-edge cell and gene therapies. T-cell therapies utilize immune cells that are genetically modified to fight cancer. The modified cells are infused into the patient to fight cancer and create long-term immunity to delay or prevent a recurrence. The facility is led by and staffed with experts in cell therapy manufacturing who will work closely with the IN8bio team to produce the DeltEx DRI cells for INB-400.
Click here for more Kentucky business news.
